Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.75 Average Target Price from Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $6.75.

Several equities research analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research report on Tuesday. Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price for the company. JMP Securities reissued a “market outperform” rating and issued a $4.00 price target (down previously from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. The Goldman Sachs Group started coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price objective for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $6.00 target price on shares of Esperion Therapeutics in a research report on Friday, December 13th.

Hedge Funds Weigh In On Esperion Therapeutics

Hedge funds have recently modified their holdings of the stock. Wasatch Advisors LP increased its position in shares of Esperion Therapeutics by 4.9% during the 4th quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company’s stock worth $53,861,000 after purchasing an additional 1,136,245 shares during the last quarter. Geode Capital Management LLC raised its position in Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after acquiring an additional 171,609 shares in the last quarter. State Street Corp grew its position in shares of Esperion Therapeutics by 2.7% in the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after acquiring an additional 99,802 shares during the period. Two Sigma Advisers LP increased its stake in shares of Esperion Therapeutics by 0.4% during the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock worth $7,956,000 after purchasing an additional 16,100 shares during the last quarter. Finally, Nuveen Asset Management LLC raised its holdings in shares of Esperion Therapeutics by 48.6% in the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock valued at $6,862,000 after purchasing an additional 1,020,243 shares during the period. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Stock Performance

NASDAQ ESPR opened at $1.65 on Monday. The stock has a market cap of $325.11 million, a price-to-earnings ratio of -2.58 and a beta of 1.01. The business has a 50 day simple moving average of $1.99 and a 200 day simple moving average of $2.09. Esperion Therapeutics has a 52-week low of $1.57 and a 52-week high of $3.94.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.